Introduction
Neuroblastoma, the most common extracranial solid tumor in childhood, develops from neural crest progenitor cells. 1, 2 Neuroblastoma accounts for ~7% of all childhood malignancies, yet is responsible for 15% of all pediatric oncology deaths.
Growing attention has been directed to genetic and geneenvironmental factors as underlying risks of neuroblastoma. Currently, numerous genetic variants have been determined to play critical roles in neuroblastoma carcinogenesis. For example, PHOX2B 13, 14 and ALK 15, 16 gene mutations were found in some neuroblastoma cases. Genome-wide association studies have also identified polymorphisms located in TP53, HACE1, BARD1, LIN28B, LMO1, and CASC15 genes associated with neuroblastoma risk. 1, 17, 18 MYCN, a member of the MYC protooncogene family, was first identified in neuroblastoma cell lines. 19 MYCN is a critical regulator of various cellular processes, including proliferation, differentiation, and apoptosis. [20] [21] [22] [23] Moreover, aberration expression of MYCN is associated with tumor initiation and progression. [24] [25] [26] Amplification of MYCN is present in ~20% of neuroblastoma cases. 27 MYCN is closely associated with aggressive tumor type and poor prognosis. 28, 29 Therefore, exploring the role of MYCN in carcinogenesis remains a research hotspot. However, few studies have been proposed to evaluate the association of MYCN gene polymorphisms and neuroblastoma risk. Given the importance of the MYCN gene in cancer initiation and development, we intend to explore whether MYCN gene polymorphisms could predispose a patient to neuroblastoma risk.
Patients and methods Participants
A total of 429 neuroblastoma cases and 884 healthy controls from 3 centers were included in this study. [30] [31] [32] All of the cases were newly confirmed and histopathologically diagnosed neuroblastoma patients without progressive disease or previous treatments. The controls were age-, gender-, and ethnicity-matched to cases and were randomly recruited from children undergoing routine medical examination at the same hospital during the same period. All of the enrolled subjects were of Chinese Han ethnicity. More specifically, 36 cases and 72 controls were enrolled from The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University (Table S1) , 275 cases and 531 controls were enrolled from Guangzhou Women and Children's Medical Center, and the remaining 118 cases and 281 controls were recruited from The First Affiliated Hospital of Zhengzhou University. Written informed consent was obtained from all of the participants' parents. Details of the selection process of the included participants were provided in our previous publication. [33] [34] [35] The institutional review board of the abovementioned 3 hospitals approved the study.
Single-nucleotide polymorphism (SNP) selection and genotyping
We chose potentially functional SNPs of interest from the dbSNP database (http://www.ncbi.nlm.nih.gov/) based on the following criteria: 1) minor allele frequency >5% for Chinese Han subjects; 2) potentially functional, such as affecting the binding capacity of transcription factor or microRNA binding sites, or leading to amino acid alterations. We chose 4 potentially functional SNPs in the MYCN gene (rs57961569 G>A, rs9653226 T>C, rs13034994 A>G, and rs60226897 G>A) for analysis. As predicted by SNPinfo (http://snpinfo. niehs.nih.gov/), all of them were located in the transcription factor binding sites. Moreover, they all had a minor allele frequency >5% in Chinese Han subjects. As shown in Figure S1 , there was no significant linkage disequilibrium (R 2 <0.8) among these 4 SNPs (R 2 =0.220 between rs57961569 and rs9653226; R 2 =0.185 between rs57961569 and rs13034994; R 2 =0.103 between rs57961569 and rs60226897; R 2 =0.348 between rs9653226 and rs13034994; R 2 =0.161 between rs9653226 and rs60226897; R 2 =0.500 between rs13034994 and rs6022689). First, the genomic DNA was extracted from the peripheral blood donated by subjects. The MYCN gene polymorphisms were detected using TaqMan real-time PCR, as described elsewhere. [36] [37] [38] [39] Eight blank wells containing water as negative controls were also placed in each 384-well plate as the means of quality control. In addition, we randomly regenotyped 10% of the samples and got a concordance rate of 100%.
Statistical analysis
Testing of Hardy-Weinberg equilibrium for the selected polymorphisms in controls was performed using a goodnessof-fit χ 2 test. A 2-sided χ 2 test was used for comparisons of 2 groups in allele frequencies and demographic variables. We evaluated the associations between genotypes and neuroblastoma risk using odds ratios (ORs) and 95% confidence intervals (CIs) calculated from logistic regression analysis. Risk genotypes were rs57961569 GG, rs9653226 CC, rs13034994 GG, and rs60226897 GG; covariates, including age and gender, were used for adjustment. Statistical analysis was performed using SAS software version 9.4 (SAS Institute, Cary, NC, USA). P-values <0.05 were considered significant.
Results

Population characteristics
The population demographics for the Guangzhou and Zhengzhou subjects were presented in our former publication. [30] [31] [32] The population demographics for the Wenzhou subjects are No statistically significant associations were found between the other 3 SNPs (rs9653226 T>C, rs13034994 A>G, and rs60226897 G>A) and neuroblastoma risk. We found that compared with subjects carrying 0-1 risk genotypes, subjects carrying 2-3 combined risk genotypes 
Discussion
In the current study, we explored the impact of SNPs of the MYCN gene on the risk of neuroblastoma in the Chinese population. Our data revealed that the rs57961569 G>A polymorphism in the MYCN gene presented significant inverse associations with neuroblastoma risk.
MYCN is located on chromosome 2p24.3 and encodes a pleiotropic nuclear phosphoprotein. The encoding protein consists of 2 domains: a carboxy-terminal DNA-binding and protein interaction domain and an amino-terminal transcriptional activation domain. In healthy conditions in humans and mice, MYCN expression is high in certain tissues in the developing embryo, while it is low or even absent in adult tissues. 40, 41 Amplification of MYCN could promote proliferation and cell cycle progression. MYCN could also enhance neuroblastoma cell migration and invasion through downregulation of integrins α1 and β1. 42, 43 Moreover, MYCN modulates antigens on the surface of tumor cells, thus influencing immune surveillance. 44 Brandetti et al 45 demonstrated that MYCN functions as an immunosuppressive oncogene in neuroblastoma cells by negatively regulating the expression In the combined analysis, subjects carrying 2-3 risk genotypes tended to have increased neuroblastoma risk in comparison to those with 0-1 risk genotypes. This phenomenon was quite biologically plausible, as a single polymorphism in each gene may not be strong enough to influence the risk of cancer. Intriguingly, stratified analysis showed that individuals harboring the rs57961569 GG alleles were more likely to have a tumor in the following subgroups: children older than 18 months, tumor derived from the adrenal gland, and clinical stages III + IV. The contributing role of the rs9653226 CC genotype to increasing neuroblastoma risk was more evident in the females, tumor derived from the adrenal gland, and clinical stages III + IV subgroups. In the stratified analysis of the cumulative effects of risk genotypes, we found that the presence of 2-3 risk genotypes had a positive relationship with the following subgroups: tumor derived from the adrenal gland and clinical stages III + IV. On one hand, the same polymorphism might have a different role in cancer risk, depending on different ethnicities, regions, and cancer types. On the other hand, a conflicting role might also be the small sample size in the stratified analysis.
Several limitations accompany the merits of this study. First, the sample size was relatively small, although we gathered samples from 3 centers, especially for the stratification analysis. As a result, the strength of the statistical power may not be strong enough. Second, being a retrospective investigation, only genetic information in the MYCN gene was measured. Measuring other environmental factors, such as childhood exposure, dietary habits, and health situation, is critical in helping to further elucidate the role of MYCN polymorphisms in neuroblastoma risk. Third, only 4 SNPs in the MYCN gene were analyzed, so more polymorphisms in the MYCN gene should be investigated.
Overall, in the Chinese population studied, we provide the first evidence that polymorphisms in MYCN gene could influence neuroblastoma risk in a low-impact manner. Larger sample size studies with additional functional analysis are needed to better elucidate the role of MYCN polymorphisms in neuroblastoma risk. Risk genotypes were rs57961569 GG, rs9653226 CC, rs13034994 GG, and rs60226897 GG. 
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